Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PNV001
MIFTS: 51

Panuveitis

Categories: Eye diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Panuveitis

About this section

MalaCards integrated aliases for Panuveitis:

Name: Panuveitis 12 52 58 54 43 15 17 71
Diffuse Uveitis 12 52
Total Uveitis 52 58
Inflammation of the Whole Uveal Tract 52

Characteristics:

Orphanet epidemiological data:

58
panuveitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:12030
ICD9CM 34 360.12
MeSH 43 D015864
NCIt 49 C84989
SNOMED-CT 67 75614007
ICD10 32 H44.11
ICD10 via Orphanet 33 H44.1
UMLS via Orphanet 72 C0030343
Orphanet 58 ORPHA280898
UMLS 71 C0030343
Sources

Summaries for Panuveitis

About this section
NIH Rare Diseases : 52 Panuveitis is inflammation of all layers of the uvea of the eye, which includes the iris , ciliary body , and choroid . These make up the middle layer of the eye. The condition can also affect the lens, retina, optic nerve, and vitreous, causing reduced vision or blindness. Signs and symptoms may include eye redness and pain; blurring; light sensitivity; decreased vision; and seeing floaters. It can last for a short time or can occur chronically. Severe cases may recur many times. In many cases the specific cause is unknown, but in some cases it occurs in association with other eye conditions, or with another condition or infection that also affects other body parts. Early treatment is needed and may include eye drops to reduce inflammation and pain; and/or oral medications or injections in severe cases.

MalaCards based summary : Panuveitis, also known as diffuse uveitis, is related to vogt-koyanagi-harada disease and sympathetic ophthalmia. An important gene associated with Panuveitis is UACA (Uveal Autoantigen With Coiled-Coil Domains And Ankyrin Repeats), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Fluocinolone Acetonide and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include eye, bone and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 An uveitis that is characterized by inflammation of all layers of the uvea (middle layer) of the eye, which includes the iris, ciliary body, and choroid.

Sources

Related Diseases for Panuveitis

About this section

Diseases in the Panuveitis family:

Infectious Panuveitis Systemic Diseases with Panuveitis

Diseases related to Panuveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 812)
# Related Disease Score Top Affiliating Genes
1 vogt-koyanagi-harada disease 33.3 IL17A IL10 HLA-DRB1 HLA-DQB1
2 sympathetic ophthalmia 33.0 TNF RBP3 IL10 HLA-DRB1
3 multifocal choroiditis 31.8 TNF IL10
4 pars planitis 31.4 MRAP HLA-DRB1 CCR6
5 punctate inner choroidopathy 31.3 TNF IL10
6 neurosyphilis 31.0 IL17A IL10
7 neuritis 31.0 TNF IL6 IL10
8 optic neuritis 30.9 TNF IL10 HLA-DRB1
9 uveitis 30.8 TNFRSF1B TNF SAG RBP3 IL6 IL17A
10 posterior uveitis 30.7 TNF SAG RBP3 MRAP IL6 CCR6
11 macular retinal edema 30.7 TNFRSF1B TNF MRAP IL6 ACE
12 intermediate uveitis 30.6 TNF MRAP IL6 IL10 HLA-DRB1 CCR6
13 conjunctivitis 30.6 TNF IL6 IL10
14 aseptic meningitis 30.6 TNF IL10 CD40LG
15 cytomegalovirus retinitis 30.6 TNF IL10 HLA-DRB1 HLA-DQB1 CD4
16 scleritis 30.5 TNFRSF1B TNF MRAP CRP CCR6
17 ocular toxoplasmosis 30.5 IL17A CD40LG
18 dengue disease 30.5 TNF CD40LG CCR6
19 histiocytosis 30.4 TNF IL17A CCR6
20 relapsing polychondritis 30.4 IL6 IL17A IL10 CRP
21 toxoplasmosis 30.4 TNF IL6 IL10 HLA-DQB1 CD40LG
22 retinal vascular disease 30.3 TNF IL6 CRP ACE
23 encephalitis 30.3 TNF IL6 IL10 CD40LG
24 cryptogenic organizing pneumonia 30.3 TNF CRP CD4
25 asymptomatic neurosyphilis 30.3 CD40LG CD4
26 choroiditis 30.3 TNF SAG RBP3 MRAP IL10 CD40LG
27 vasculitis 30.2 TNFRSF1B TNF IL6 IL17A IFNA2 CRP
28 histoplasmosis 30.2 TNFRSF1B TNF HLA-DRB1 CD40LG CD4 CCR6
29 toxocariasis 30.2 MRAP CRP CD40LG
30 igg4-related disease 30.2 CRP CD4 CCR6
31 neuroretinitis 30.2 SAG MRAP CRP CD40LG CD4 ACE
32 visceral leishmaniasis 30.2 TNF IL10 HLA-DRB1 CRP
33 endophthalmitis 30.2 TNF SAG MRAP IL6 CRP CD4
34 whipple disease 30.2 MRAP HLA-DRB1 HLA-DQB1 CRP
35 periodic fever, familial, autosomal dominant 30.2 TNFRSF1B TNF IL6
36 peritonitis 30.2 TNF IL6 IL10 CRP
37 human immunodeficiency virus infectious disease 30.2 TNF IL10 CD4 CCR6
38 cardiogenic shock 30.2 IL6 CRP
39 multiple cranial nerve palsy 30.2 CRP ACE
40 lymphadenitis 30.2 TNF IL10 CRP CD4 CCR6
41 pustulosis of palm and sole 30.1 TNFRSF1B TNF MRAP IL17A CCR6
42 retinal vasculitis 30.1 TNFRSF1B SAG RBP3 MRAP CD40LG CCR6
43 autoimmune uveitis 30.1 TNF SAG RBP3 IL17A IL10
44 birdshot chorioretinopathy 30.1 MRAP IL17A ERAP2 ERAP1 CCR6
45 erythema elevatum diutinum 30.1 TNFRSF1B CD40LG
46 cutaneous leishmaniasis 30.1 TNF IL6 IL17A IL10
47 cat-scratch disease 30.1 CRP CD40LG CD4 ACE
48 allergic hypersensitivity disease 30.1 TNF IL17A IL10 CD4 CCR6
49 hypopyon 30.0 TNFRSF1B RBP3 MRAP IL6 IL17A CRP
50 guillain-barre syndrome 30.0 TNFRSF1B TNF HLA-DRB1 HLA-DQB1 CD40LG

Graphical network of the top 20 diseases related to Panuveitis:



Diseases related to Panuveitis
Sources

Symptoms & Phenotypes for Panuveitis

About this section

GenomeRNAi Phenotypes related to Panuveitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 ACE CD40LG HLA-DQB1 IL10 IL17A TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ACE CD40LG HLA-DQB1 IL10 IL17A TNF

MGI Mouse Phenotypes related to Panuveitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.18 ACE CD4 CD40LG ERAP1 HLA-DQB1 IL10
2 homeostasis/metabolism MP:0005376 10.17 ACE CCR6 CD4 CD40LG CRP HLA-DQB1
3 hematopoietic system MP:0005397 10.15 ACE CCR6 CD4 CD40LG ERAP1 HLA-DQB1
4 cardiovascular system MP:0005385 10.13 ACE CCR6 CD40LG CRP HLA-DQB1 IL10
5 immune system MP:0005387 10.07 ACE CCR6 CD4 CD40LG CRP ERAP1
6 liver/biliary system MP:0005370 9.76 ACE HLA-DQB1 IL10 IL6 MRAP TNF
7 renal/urinary system MP:0005367 9.56 ACE CD40LG ERAP1 HLA-DQB1 IL17A IL6
8 respiratory system MP:0005388 9.23 HLA-DQB1 IL10 IL17A IL6 MRAP TNF
Sources

Drugs & Therapeutics for Panuveitis

About this section

Drugs for Panuveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3
Chlorambucil Approved Phase 4 305-03-3 2708
4
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
5
Azathioprine Approved Phase 4 446-86-6 2265
6
Infliximab Approved Phase 4 170277-31-3
7
Mycophenolic acid Approved Phase 4 24280-93-1 446541
8 Cyclosporins Phase 4
9 Alkylating Agents Phase 4
10 Melanocyte-Stimulating Hormones Phase 4
11 Adrenocorticotropic Hormone Phase 4
12 beta-endorphin Phase 4
13
Adalimumab Approved Phase 3 331731-18-1 16219006
14
Difluprednate Approved Phase 3 23674-86-4 443936
15
Fluprednisolone Approved Phase 3 53-34-9
16
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
17
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
18
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
19
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
20 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
21
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
22
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
23
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
24 Triamcinolone diacetate Phase 3
25 triamcinolone acetonide Phase 3
26 Triamcinolone hexacetonide Phase 3
27 Methylprednisolone Acetate Phase 3
28 Anti-Infective Agents Phase 3
29 Antiviral Agents Phase 3
30 Interferon-alpha Phase 3
31 Interferon alpha-2 Phase 3
32 interferons Phase 3
33 Calcineurin Inhibitors Phase 3
34 Antibiotics, Antitubercular Phase 3
35 Anti-Bacterial Agents Phase 3
36 Antitubercular Agents Phase 3
37 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
38 Antibodies, Monoclonal Phase 3
39 Antibodies Phase 3
40 Immunoglobulins Phase 3
41 Pharmaceutical Solutions Phase 3
42
tannic acid Approved Phase 2 1401-55-4
43
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
44
Leflunomide Approved, Investigational Phase 2 75706-12-6 3899
45
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
46
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
47
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
48
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
49
Methotrexate Approved Phase 1, Phase 2 1959-05-2, 59-05-2 126941
50
leucovorin Approved Phase 1, Phase 2 58-05-9 6006 143

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
2 A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis NIPPU Recruiting NCT03656692 Phase 4 Acthar
3 A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
4 Phase 3 Open-Labeled Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Severe Anterior Uveitis (Including Panuveitis). Completed NCT00407056 Phase 3 Difluprednate Ophthalmic Emulsion
5 Phase 3 Confirmatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Including Panuveitis). Completed NCT00406887 Phase 3 Difluprednate Ophthalmic Emulsion
6 Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis Completed NCT03097315 Phase 3
7 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
8 Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet`s Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
9 A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis Completed NCT00404885 Phase 3 Placebo;LX211;LX211;LX211
10 A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quiescent Sight Threatening, Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
11 A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
12 A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT02748512 Phase 3 FAI insert
13 A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT01148225 Phase 3 adalimumab
14 A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
15 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01138657 Phase 3 Prednisone;Placebo
16 First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial Completed NCT01829295 Phase 3 Mycophenolate mofetil;Methotrexate;Prednisone
17 A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye Active, not recruiting NCT01694186 Phase 3 FAI insert;Sham injection
18 A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye Active, not recruiting NCT02746991 Phase 3 Sham Injection;FAI Insert
19 A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study) Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
20 A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis. Terminated NCT01032915 Phase 3 Placebo
21 A 34-week Extension to a 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior, or Panuveitis Requiring Immunosuppression (INSURE Study) Terminated NCT01103024 Phase 3
22 A 38-week Extension to a 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet's Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy (SHIELD Study) Terminated NCT01093846 Phase 3 AIN457;AIN457;Placebo AIN457
23 A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis Terminated NCT01090310 Phase 3 AIN457;Placebo
24 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis Terminated NCT01684345 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
25 An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects With Non Infectious Intermediate-, Posterior-, or Pan-Uveitis Patients Who Each Successfully Completed Either the X052130/CL3-78989-005 (EYEGUARDâ„¢-A) or the X052131/CL3-78989-006 (EYEGUARDâ„¢-C) Study or Who Have Controlled Ocular Inflammation After Receiving Study Drug in Study X052133 (EYEGUARDâ„¢-US) Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
26 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment Terminated NCT01747538 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
27 A Multicenter, Open-label Study to Evaluate the Long Term Clinical Use of Treatment With AIN457 in Patients Completing Clinical Trials Investigating AIN457 for the Treatment of Non-infectious Intermediate, Posterior or Panuveitis Withdrawn NCT01327664 Phase 3
28 Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Unknown status NCT01717170 Phase 1, Phase 2 Tocilizumab
29 A Multicenter, Single Sequence, Open-label Study to Assess the Tolerability, Safety, and Efficacy of 2 Weeks Oral AEB071 300 mg Twice Daily, Followed by 6 Weeks AEB071 200 mg Twice Daily in the Treatment of Patients With Macular Edema Associated With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT00615693 Phase 2 AEB071
30 An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis Completed NCT00685399 Phase 2 AIN457;AIN 457;AIN457
31 Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
32 A Randomized, Active-controlled, Open-label, Multicenter proof-of Concept Study of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, Posterior-, or Panuveitis Requiring Systemic Immunosuppressive Therapy Completed NCT01526889 Phase 2 LFG316;Conventional Therapy
33 Phase 2a Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Inluding Iritis, Cyclitis, Iridocyclitis, and Panuveitis). Completed NCT00405496 Phase 2 Difluprednate Ophthalmic Emulsion
34 A Randomized, Masked, Multicenter Study to Assess the Safety and Efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Following Uveitis Completed NCT02255032 Phase 2 4 mg CLS-TA;0.8 mg CLS-TA
35 Pilot Study of Leflunomide for the Treatment of Uveitis Completed NCT00001863 Phase 2 Leflunomide
36 A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis Recruiting NCT03308045 Phase 1, Phase 2
37 A Pilot Study to Investigate Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis Recruiting NCT02911116 Phase 2 Ustekinumab;Ustekinumab
38 Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis Recruiting NCT01280669 Phase 2 Intravitreal injection 440mcg;Intravitreal injection of sirolimus 880mcg
39 A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU) Recruiting NCT03847272 Phase 2 prednisone and ustekinumab treatment
40 A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease Active, not recruiting NCT02648581 Phase 2 Subcutaneous Ustekinumab
41 Treatment of Non-infectious Panuveitis, Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate Terminated NCT01314417 Phase 1, Phase 2 Methotrexate
42 A Multicenter, Randomized, Active-controlled Study to Assess the Safety, Tolerability, and Efficacy of FTY720 in Patients With Acute, Noninfectious Intermediate, Posterior and Pan Uveitis Withdrawn NCT01791192 Phase 2 FTY720;Oral Corticosteroid
43 A Pilot Study to Investigate Ustekinumab (StelaraTM) for the Treatment of Active Sight-Threatening Uveitis Withdrawn NCT01647152 Phase 1, Phase 2 Ustekinumab
44 A Phase I/IIa Study of the Treatment of None-Infectious Anterior, Intermediate, Posterior and Panuveitis, With the Use of Dexamethasone Delivered by a Iontophoresis Device Withdrawn NCT00499551 Phase 1, Phase 2
45 A Phase 1, Open-label, Randomized Clinical Study to Assess the Safety, Tolerability and Bioactivity of Intravitreal and Subconjunctival Injection of Sirolimus in Patients With Non-infectious Uveitis Completed NCT00908466 Phase 1 Sirolimus (rapamycin);Sirolimus (rapamycin)
46 The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma Completed NCT00943982 Phase 1 Interferon Gamma 1-b
47 Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis Active, not recruiting NCT01781936 Phase 1 Fluocinolone Acetonide
48 Quality of Life and Visual Function in Uveitis Patients Unknown status NCT00407316
49 Multi-Center, Non-Interventional Extension Study of the Safety and Efficacy of CLS-TA for the Treatment of Macular Edema Associated With Non-Infectious Uveitis Completed NCT02952001 4mg CLS-TA Suprachoriodal Injection
50 Combined Fluocinolone Acetonide Sustained Drug Delivery System Implantation and Phacoemulsification/Intraocular Lens Implantation in Patients With Severe Uveitis Completed NCT00570830

Search NIH Clinical Center for Panuveitis

Cochrane evidence based reviews: panuveitis

Sources

Genetic Tests for Panuveitis

About this section
Sources

Anatomical Context for Panuveitis

About this section

MalaCards organs/tissues related to Panuveitis:

40
Eye, Bone, T Cells, Skin, Retina, Thyroid, B Cells
Sources

Publications for Panuveitis

About this section

Articles related to Panuveitis:

(show top 50) (show all 1371)
# Title Authors PMID Year
1
Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study. 54 61
9713053 1998
2
Diagnostic dilemma: Unilateral panuveitis mimicking endophthalmitis in very severe HLA B27-associated uveitis. 61
31970307 2020
3
The Detection of Occult Retinal Vasculitis on Fluorescein Angiography in Pediatric Uveitis. 61
31708487 2020
4
Epidemiology of uveitis in a region of southern Sweden. 61
31161663 2020
5
HISTOLOGIC FINDINGS IN VITREORETINAL LYMPHOMA: Learning From Enucleation Specimens. 61
31972811 2020
6
Intravitreal thalidomide ameliorates inflammation in a model of experimental uveitis induced by BCG. 61
32018067 2020
7
Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. 61
32006221 2020
8
Ocular Manifestations In Late Onset Behçet's Disease. 61
31994475 2020
9
Ocular Features in Chinese Patients with Blau Syndrome. 61
30806112 2020
10
Appearance of pediatric choroidal neovascular membranes on optical coherence tomography angiography. 61
31758259 2020
11
Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS) - Report 2: Pattern of Uveitis Investigations in Singapore. 61
30335550 2020
12
Bilateral enucleation due to multi-bacterial fulminant endogenous panophthalmitis. 61
31767407 2020
13
Relationship of Epiretinal Membrane Formation and Macular Edema Development in a Large Cohort of Uveitic Eyes. 61
31961201 2020
14
Altered gut microbiome composition in patients with Vogt-Koyanagi-Harada disease. 61
31928124 2020
15
Multiple Granulomas of Ocular Toxocariasis in an Immunocompetent Male. 61
31157988 2020
16
Ozurdex (dexamethasone intravitreal implant) for the treatment of intermediate, posterior, and panuveitis: a systematic review of the current evidence. 61
31925591 2020
17
[Treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis]. 61
31818505 2019
18
Visual Acuity Outcome over Time in Non-Infectious Uveitis. 61
31821051 2019
19
Resurgence of ocular syphilis in British Columbia between 2013-2016: a retrospective chart review. 61
31889521 2019
20
Sustained Control from Recurring Non-Infectious Uveitic Macular Edema with 0.19 mg Fluocinolone Acetonide Intravitreal Implant - A Case Report. 61
31506865 2019
21
Inflammatory Relapses after Immunosuppressive Drug Discontinuation in Uveitis Patients: A Survival Analysis. 61
31710514 2019
22
Erythema elevatum et diutinum as a systemic disease. 61
31864448 2019
23
Bilateral exudative retinal detachment in undiagnosed ocular syphilis after treatment with corticosteroids. 61
31746221 2019
24
Retinal Function in Patients with Adalimumab Treatment: Long-term Follow-up with Microperimetry. 61
31697184 2019
25
[Systemic biological treatment in ophthalmology]. 61
31657252 2019
26
Ethnicity and association with ocular, systemic manifestations and prognosis in 194 patients with sarcoid uveitis. 61
31302765 2019
27
Adalimumab for non-infectious uveitis: is it cost-effective? 61
30728124 2019
28
Bartonella henselae- and quintana-associated uveitis: a case series and approach of a potentially severe disease with a broad spectrum of ocular manifestations. 61
30852734 2019
29
Induction of ocular Behçet's disease remission after short-term treatment with infliximab: a case series of 11 patients with a follow-up from 4 to 16 years. 61
31856941 2019
30
Diagnostic vitrectomy: a case series in a single referral center. 61
31606240 2019
31
Artisan-style iris-claw intraocular lens implantation in patients with uveitis. 61
31585851 2019
32
IgA Nephropathy-Associated Uveitis: A Case Presentation. 61
31580182 2019
33
[Epidemiologic and etiologic patterns of uveitis in a University Hospital]. 61
31164299 2019
34
HISTOLOGIC FINDINGS IN VITREORETINAL LYMPHOMA: Learning From Enucleation Specimens. 61
31613837 2019
35
Multimodal Imaging of Parry Romberg Syndrome-associated Panuveitis: A Case Report and Review of Literature. 61
31577463 2019
36
Autologous Descemet Stripping Automated Endothelial Keratoplasty to Eliminate Endothelial Rejection in Eyes at High Risk. 61
31688200 2019
37
Choroidal Infiltration as First Clinical Manifestation of T-cell Large Granular Lymphocyte (T-LGL) Leukemia. 61
31577464 2019
38
Fungal Endogenous Endophthalmitis during Pregnancy as a Complication of In-Vitro Fertilization. 61
31664877 2019
39
Sympathetic ophthalmia with incidental finding of chicken pox supported by histopathology and immunohistochemistry. 61
31611447 2019
40
Youngest reported Seasonal Hyperacute Panuveitis case. 61
31372583 2019
41
Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. 61
31607412 2019
42
Irreversible Ocular Lesions in a Dog With Angiostrongylus Vasorum Infection. 61
31472726 2019
43
Retinal detachment and uveitis at a tertiary center over 10 years: the King Khaled Eye Specialist Hospital (KKESH) Uveitis Survey Study Group. 61
31177301 2019
44
Etiologic Spectrum and Follow-Up Results of Noninfectious Uveitis in Children: A Single Referral Center Experience. 61
31598595 2019
45
Atypical herpes simplex virus type 2 acute retinal necrosis presentation with large subretinal lesion. 61
31304428 2019
46
Uveitis: Autoimmunity… and beyond. 61
31323361 2019
47
The localization of a conjunctivoscleral foreign body via high-resolution microscopy coil magnetic resonance imaging in a dog. 61
30977286 2019
48
Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial. 61
31503307 2019
49
Uveitis and health disparities: results from the National Inpatient Sample. 61
30578244 2019
50
Clinical Presentation, Management and Long Term Outcome of Pars Planitis (PP), Panuveitis (PU) and Vogt-Koyanagi-Harada disease (VKH) in Children and Adolescents. 61
31444859 2019
Sources

Variations for Panuveitis

About this section
Sources

Expression for Panuveitis

About this section
Search GEO for disease gene expression data for Panuveitis.
Sources

Pathways for Panuveitis

About this section

Pathways related to Panuveitis according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.97 TNFRSF1B TNF IL6 IL17A IL10 IFNA2
2
PEDF Induced Signaling 63
Show member pathways
 13.66 TNFRSF1B TNF IL6 IL17A IL10 IFNA2
3
Akt Signaling 63
Show member pathways
 13.4 TNFRSF1B TNF IL6 IL17A IL10 CD40LG
4
PAK Pathway 63
Show member pathways
 13.28 TNFRSF1B TNF IL6 IL17A IL10 CD40LG
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.24 TNFRSF1B TNF IL6 IL17A IL10 IFNA2
6
Herpes simplex virus 1 infection 36
12.77 TNF IL6 IFNA2 HLA-DRB1 HLA-DQB1
7
T cell receptor signaling pathway 36
Show member pathways
 12.59 TNF IL6 IL17A IL10 CD40LG CD4
8
Immune response IL-23 signaling pathway 22
Show member pathways
 12.58 TNF IL6 IL17A IL10 CD4
9
Immune response NFAT in immune response 22
Show member pathways
 12.58 TNFRSF1B TNF IL10 HLA-DRB1 HLA-DQB1 CD40LG
10
NF-kappaB Signaling 4
12.55 TNFRSF1B TNF IL17A IL10 CD40LG
11
Th17 cell differentiation 36
Show member pathways
 12.45 TNF IL6 IL17A IL10 HLA-DRB1 HLA-DQB1
12
ICos-ICosL Pathway in T-Helper Cell 63
Show member pathways
 12.36 HLA-DRB1 HLA-DQB1 CD40LG CD4
13
Allograft rejection 1 36
Show member pathways
 12.35 TNF IL6 IL17A IL10 IFNA2 HLA-DRB1
14
Human T-cell leukemia virus 1 infection 36
12.34 TNF IL6 HLA-DRB1 HLA-DQB1 CD4
15
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.33 TNFRSF1B TNF IL6 IL10 CCR6
16
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.26 TNF IL6 IL17A IL10 IFNA2
17
Toxoplasmosis 36
Show member pathways
 12.26 TNF IL10 HLA-DRB1 HLA-DQB1 CD40LG
18
Cell adhesion molecules (CAMs) 36
12.11 HLA-DRB1 HLA-DQB1 CD40LG CD4
19
Th1 Differentiation Pathway 64
Show member pathways
 12.04 TNF IL6 IL17A IL10 CD4
20
Tuberculosis 36
11.99 TNF IL6 IL10 IFNA2 HLA-DRB1 HLA-DQB1
21
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.97 TNF IL6 IL10 IFNA2 CD4
22
Interleukin-4 and 13 signaling 65
11.95 TNFRSF1B TNF IL6 IL17A IL10
23
Hematopoietic cell lineage 36
11.85 TNF IL6 HLA-DRB1 HLA-DQB1 CD4
24
Rheumatoid arthritis 36
11.77 TNF IL6 IL17A HLA-DRB1 HLA-DQB1
25
G-protein signaling N-RAS regulation pathway 22
Show member pathways
 11.76 HLA-DRB1 HLA-DQB1 CD4
26
Pertussis 36
11.73 TNF IL6 IL10
27
Microglia Activation During Neuroinflammation: Microglia Polarization 64
11.73 TNF IL6 IL17A IL10
28
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 22
Show member pathways
 11.71 TNFRSF1B TNF CD40LG
29
CTLA4 Signaling 63
11.7 HLA-DRB1 HLA-DQB1 CD4
30
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.64 TNF IL6 CD40LG
31
Innate Lymphoid Cell Differentiation Pathways 64
11.62 TNF IL17A IL10 CD4 CCR6
32
B Cell Development Pathways 64
11.56 IL10 CD40LG CD4
33
Malaria 36
11.56 TNF IL6 IL10 CD40LG
34
Interleukin-10 signaling 65
11.54 TNFRSF1B TNF IL6 IL10
35
Dendritic Cells Developmental Lineage Pathway 64
11.42 TNF IL6 IL10 IFNA2 CD4
36
African trypanosomiasis 36
11.38 TNF IL6 IL10
37
IL-10 Pathway 63
11.34 TNF IL6 IL10
38
Development and heterogeneity of the ILC family 1
11.3 TNF IL6 IL17A
39
Overview of nanoparticle effects 1
11.05 TNF IL6 CRP
40
Cytokines and Inflammatory Response 1
10.48 TNF IL6 IL10 HLA-DRB1 CD4
Sources

GO Terms for Panuveitis

About this section

Cellular components related to Panuveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.85 TNF RBP3 IL6 IL17A IL10 IFNA2
2 external side of plasma membrane GO:0009897 9.5 TNF IL17A HLA-DRB1 CD40LG CD4 CCR6
3 extracellular region GO:0005576 9.44 UACA TNFRSF1B TNF RBP3 IL6 IL17A

Biological processes related to Panuveitis according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.93 TNFRSF1B SAG IFNA2 CD4
2 adaptive immune response GO:0002250 9.91 IFNA2 HLA-DRB1 ERAP2 ERAP1 CD4
3 cellular response to lipopolysaccharide GO:0071222 9.86 TNFRSF1B TNF IL6 IL10
4 B cell differentiation GO:0030183 9.8 IL10 IFNA2 CD40LG
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 TNF IL6 IFNA2
6 response to glucocorticoid GO:0051384 9.78 TNF IL6 IL10
7 regulation of blood pressure GO:0008217 9.75 ERAP2 ERAP1 ACE
8 positive regulation of T cell proliferation GO:0042102 9.74 IL6 CD40LG CD4
9 cytokine-mediated signaling pathway GO:0019221 9.7 TNFRSF1B TNF IL6 IL17A IL10 IFNA2
10 B cell proliferation GO:0042100 9.65 IL10 IFNA2 CD40LG
11 regulation of neuroinflammatory response GO:0150077 9.62 TNFRSF1B IL6
12 humoral immune response GO:0006959 9.62 TNF IL6 IFNA2 CCR6
13 positive regulation of JAK-STAT cascade GO:0046427 9.61 TNF IL6 IL10
14 endothelial cell apoptotic process GO:0072577 9.6 TNF IL10
15 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0019885 9.59 ERAP2 ERAP1
16 neutrophil mediated immunity GO:0002446 9.58 IL6 ACE
17 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.58 ERAP2 ERAP1 ACE
18 inflammatory response GO:0006954 9.56 TNFRSF1B TNF IL6 IL17A IL10 IFNA2
19 negative regulation of cytokine secretion involved in immune response GO:0002740 9.55 TNF IL10
20 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.54 HLA-DRB1 HLA-DQB1
21 peptide catabolic process GO:0043171 9.54 ERAP2 ERAP1 ACE
22 regulation of immunoglobulin secretion GO:0051023 9.52 TNF CD40LG
23 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.49 HLA-DRB1 HLA-DQB1
24 receptor biosynthetic process GO:0032800 9.46 TNF IL10
25 negative regulation of lipid storage GO:0010888 9.43 TNF IL6 CRP
26 immune response GO:0006955 9.32 TNFRSF1B TNF IL6 IL17A IL10 HLA-DRB1

Molecular functions related to Panuveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 TNF IL6 IL17A IL10 IFNA2 CD40LG
2 interleukin-6 receptor binding GO:0005138 8.96 IL6 ERAP1
Sources

Sources for Panuveitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....